This GHRP peptide blend combines 1.5 mg of either GHRP-6 or GHRP-2 with Mod GRF(1-29) / CJC without DAC, available in 0.6 mg or 2 mg options for flexible experimental design. GHRP-6 and GHRP-2 are growth hormone secretagogues widely used in research to study ghrelin-receptor activity, pituitary signaling, and targeted GH release. Mod GRF(1-29) supports pulsatile growth hormone stimulation via GHRH-mediated receptor engagement under controlled laboratory conditions.
Researchers select this blend to explore dual-pathway growth hormone signaling, enabling simultaneous investigation of GHSR-driven activation alongside stabilized GHRH analogue interaction. This supports advanced modeling of GH-pulse dynamics, response timing, and downstream endocrine regulation.
Common laboratory applications for this GHRP peptide blend include:
Analysing synergistic GH secretion in vitro or ex vivo
Mapping pituitary-driven signaling cascades
Studying receptor selectivity and pathway cross-talk
Comparing GHRP-2 vs GHRP-6 behavior within dual-peptide systems
Because both components deliver reproducible signaling characteristics in research environments, the formulation supports consistent data generation and structured mechanistic studies. The ability to choose between 0.6 mg and 2 mg of Mod GRF(1-29) provides controlled experimental flexibility to match study duration and peptide exposure requirements.
This GHRP peptide blend is supplied exclusively for regulated scientific research. It is not approved for human or veterinary administration, therapeutic or diagnostic use, or any medical application. All handling must follow institutional biosafety protocols and relevant regulatory standards.
For research use only. Not for human consumption.
Researchers select this blend to explore dual-pathway growth hormone signaling, enabling simultaneous investigation of GHSR-driven activation alongside stabilized GHRH analogue interaction. This supports advanced modeling of GH-pulse dynamics, response timing, and downstream endocrine regulation.
Common laboratory applications for this GHRP peptide blend include:
Analysing synergistic GH secretion in vitro or ex vivo
Mapping pituitary-driven signaling cascades
Studying receptor selectivity and pathway cross-talk
Comparing GHRP-2 vs GHRP-6 behavior within dual-peptide systems
Because both components deliver reproducible signaling characteristics in research environments, the formulation supports consistent data generation and structured mechanistic studies. The ability to choose between 0.6 mg and 2 mg of Mod GRF(1-29) provides controlled experimental flexibility to match study duration and peptide exposure requirements.
This GHRP peptide blend is supplied exclusively for regulated scientific research. It is not approved for human or veterinary administration, therapeutic or diagnostic use, or any medical application. All handling must follow institutional biosafety protocols and relevant regulatory standards.
For research use only. Not for human consumption.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Not a researcher? Exit
